Inventor · disambiguated record
Karen G. Bulock
Also filed as: BULOCK KAREN G
8 granted patents·4 pending applications·138 citations·filing 2006–2021
89Inventor score
Top patents by PatentIndex Score
12 records- 0197US10913948B2RNA interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2018·Granted Feb 9, 2021·21 cites·7 claims
- 0297US9340786B2RNA interference in dermal and fibrotic indicationsKHVOROVA ANASTASIA·Filed 2011·Granted May 17, 2016·49 cites·20 claims
- 0396US9963702B2RNA interference in dermal and fibrotic indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted May 8, 2018·23 cites·20 claims
- 0495US10138485B2Neutral nanotransportersKHVOROVA ANASTASIA·Filed 2009·Granted Nov 27, 2018·22 cites·15 claims
- 0591US11001845B2Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)PHIO PHARM CORP·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 0690US11396654B2Neutral nanotransportersPHIO PHARM CORP·Filed 2018·Granted Jul 26, 2022·4 cites·19 claims
- 0786US11021707B2Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAPHIO PHARM CORP·Filed 2016·Granted Jun 1, 2021·7 cites·19 claims
- 0883US11279934B2Methods for treating cancer using nucleic acids targeting MDM2 or MYCNPHIO PHARM CORP·Filed 2015·Granted Mar 22, 2022·5 cites·8 claims
- 0972US2021261968A1Rna interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2021·Application pending·0 cites
- 1046US2016304875A1Methods for treatment of wound healing utilizing chemically modified oligonucleotidesRXI PHARMACEUTICALS CORP·Filed 2014·Application pending·0 cites
- 1136US2007015720A1Modulation of endogenous AICAR levels for the treatment of diabetes and obesityCYTRX CORP·Filed 2006·Application pending·0 cites
- 1233US2017051290A1Methods for treatment of disorders in the front of the eye utilizing nucleic acid moleculesRXI PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →